Probo Medical Acquires Canute Medical

Probo Medical notes Canute is led today by Ben Rice and supported by a team of medical equipment professionals with a deep understanding of the large imaging equipment markets.

Probo Medical (“Probo”), a leading global provider of medical imaging equipment, parts, repair and service, today announced the completion of its acquisition of Canute Medical (“Canute”). Terms of the transaction were not disclosed.

Canute, incorporated in 2012, is a leading service provider for installation, de-installation, removals, and remarketing of pre-owned medical equipment such as MRI, CT, X-Ray and Gamma Cameras for clients around the world. Based in Oakville, Ontario, Canute is led today by Ben Rice and supported by a team of medical equipment professionals with a deep understanding of the large imaging equipment markets.

“We’re fortunate to have Ben and his team at Canute join the Probo family as they will add tremendous expertise to our team,” said Michael Asmer, CEO of Probo Medical. “With this expansion, we look forward to growing our presence in Canada with a recognized team in the industry.”

Ben Rice, Director of Canute Medical, “Aligning with Probo connects the Canute team to a platform that will enhance our services for customers. We see a great opportunity ahead for the expansion of the solutions we can bring to the market.”

Probo Medical is backed by Avista Capital Partners, a leading New York-based private equity firm with more than 40 growth-oriented healthcare businesses globally.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.